San Diego, CA – January 27, 2025 – Antharis Therapeutics, a biopharmaceutical company advancing cutting-edge immunotherapeutic treatments in oncology, proudly announces its recognition as the Monoclonal Antibodies Development Company of the Year 2025, celebrating its trailblazing contributions to precision immuno-oncology and cancer treatment innovation. Antharis was selected amongst its peers after an exhaustive evaluation by an expert panel of C-level executives, industry thought leaders and the editorial board of Life Sciences Review, which presented the award.
In an era where immune evasion remains a critical challenge in oncology, Antharis is a top emerging company leading the charge with next-generation monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) that redefine therapeutic precision and efficacy. Its cutting-edge therapies combine biomarker-driven targeting with advanced immunoe-oncology approaches to eradicate malignant cells while sparing healthy tissues.
“I am deeply honored and humbled by the recognition of Antharis as the Monoclonal Antibodies Development Company of the Year 2025. This award, which reflects the esteem of leaders and companies we greatly admire in our sector, serves as a powerful motivation for us to continue advancing next-generation biotherapeutics that may transform the lives of patients battling various forms of cancer,” said Dr. Raphael Ribeiro-Pinaud, Chairman and CEO of Antharis Therapeutics.
He further emphasized: “Our therapies are founded on scientific rigor and fueled by innovation, making this recognition a meaningful validation of our unwavering commitment to transforming patient outcomes and shaping a healthier future for all.”
This accolade underscores Antharis Therapeutics’ growing impact within the biopharmaceutical industry and its relentless pursuit of breakthroughs in oncology. As the company continues to expand and advance its pipeline of innovative monoclonal antibodies and antibody-drug conjugates, Antharis remains dedicated to collaborating with global partners, clinicians, and researchers to accelerate the delivery of life-changing therapies to patients worldwide. Our company is working hard to re-shape the landscape of cancer treatment, setting a new standard in precision, adaptability, and hope for patients globally.
Read the Full Article
For a deeper dive into Antharis Therapeutics’ journey and the innovations driving its success, read the full article here.
About Antharis Therapeutics
Antharis Therapeutics is a top emerging biopharmaceutical company focused on developing innovative monoclonal antibody therapies for oncology and other critical medical fields. The company’s core approach to cancer treatment leverages the power of immuno-oncology, enhancing the body’s immune response to fight cancer. With a robust pipeline of dozens of therapies in various levels of development and a multidisciplinary team of experts, Antharis is dedicated to transforming the future of healthcare by delivering safe, effective, and life-changing treatments to patients in need. For more information, please visit www.antharistherapeutics.com.
